Is hepatotoxicity in patients treated with gemtuzumabozogamicin due to specific targeting of hepatocytes?

Leukemia Research

Volumn 35, Issue 6, 2011, Pages

  Maniecki, Maciej Bogdan ^a   Hasle, Henrik ^a   Bendix, Knud ^b   Møller, Holger Jon ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b University Institute of Pathology Arhus   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CD163 ANTIGEN; CD33 ANTIGEN; GEMTUZUMAB OZOGAMICIN;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER SURVIVAL; DRUG SAFETY; HUMAN; HYPERBILIRUBINEMIA; IMMUNOPATHOLOGY; KUPFFER CELL; LETTER; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LIVER CELL; LIVER TOXICITY; LIVER VENOOCCLUSIVE DISEASE; MACROPHAGE; MACROPHAGE DEPLETION SYNDROME; PRIORITY JOURNAL; PROGNOSIS; SIDE EFFECT;

ACUTE DISEASE; AMINOGLYCOSIDES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ANTINEOPLASTIC AGENTS; DRUG-INDUCED LIVER INJURY; HEPATOCYTES; HUMANS; IMMUNOHISTOCHEMISTRY; LEUKEMIA, MYELOID;

EID: 79955610371     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.01.025     Document Type: Letter

References (10)

1. Voutsadakis I.A. Gemtuzumab Ozogamicin (CMA-676, Mylotarg) for the treatment of CD33+ acute myeloid leukemia. Anticancer Drugs 2002, 13(7):685-692.
2. Sievers E.L. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukaemia in first relapse. Expert Opin Biol Ther 2001, 1(5):893-901.
3. Sievers E.L., Linenberger M. Mylotarg: antibody-targeted chemotherapy comes of age. Curr Opin Oncol 2001, 13(6):522-527.
4. Bross P.F., Beitz J., Chen G., Chen X.H., Duffy E., Kieffer L., et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 2001, 7(6):1490-1496.
5. Arceci R.J., Sande J., Lange B., Shannon K., Franklin J., Hutchinson R., et al. Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia. Blood 2005, 106(4):1183-1188.
6. Burnett A.K., Hills R.K., Milligan D., Kjeldsen L., Kell J., Russell N.H., et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol 2010.
7. Lowenberg B., Beck J., Graux C., van P.W., Schouten H.C., Verdonck L.F., et al. Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study. Blood 2010, 115(13):2586-2591.
8. McKoy J.M., Angelotta C., Bennett C.L., Tallman M.S., Wadleigh M., Evens A.M., et al. Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project. Leuk Res 2007, 31(5):599-604.
9. Larson R.A., Sievers E.L., Stadtmauer E.A., Lowenberg B., Estey E.H., Dombret H., et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 2005, 104(7):1442-1452.
10. Maniecki M.B., Hasle H., Friis-Hansen L., Lausen B., Nielsen O.J., Bendix K., et al. Impaired CD163-mediated hemoglobin-scavenging and severe toxic symptoms in patients treated with gemtuzumab ozogamicin. Blood 2008, 112(4):1510-1514.